Michael A Morse, Arvind Chaudhry, Elizabeth S Gabitzsch, Amy C Hobeika, Takuya Osada, Timothy M Clay, Andrea Amalfitano, Bruce K Burnett, Gayathri R Devi, David S Hsu, Younong Xu, Stephanie Balcaitis, Rajesh Dua, Susan Nguyen, Joseph P Balint, Frank R Jones, H Kim Lyerly
First-generation, E1-deleted adenovirus subtype 5 (Ad5)-based vectors, although promising platforms for use as cancer vaccines, are impeded in activity by naturally occurring or induced Ad-specific neutralizing antibodies. Ad5-based vectors with deletions of the E1 and the E2b regions (Ad5 [E1-, E2b-]), the latter encoding the DNA polymerase and the pre-terminal protein, by virtue of diminished late phase viral protein expression, were hypothesized to avoid immunological clearance and induce more potent immune responses against the encoded tumor antigen transgene in Ad-immune hosts...
August 2013: Cancer Immunology, Immunotherapy: CII